PharmaLive
LONDON, Oct. 10, 2007:Ark Therapeutics Group plc ('Ark') today announces that it has signed an agreement to spin out its non-core discovery stage anti-angiogenic peptides and peptoid leads and associated science to Eyecopharm AG ('Eyecopharm' or the 'Company'), a newly formed company focused specifically on eye diseases. Eyecopharm has been founded in Hamburg by Professor Heinrich M Schulte, the renowned biotech entrepreneur and founder of Evotec AG and Endokrinologikum Medical, a rapidly growing medical care and diagnostics group in Germany.